BRI, BMI, and VIDAC Score Relationship in Obese Patients

ConditionVidiac Score
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-65
SponsorSamsun University

About this trial

The VIDIAC score is a measurement system that objectively defines glottic visibility and anatomical complexity in videolaryngoscopy. The literature has shown a relationship between parameters such as BMI, NC, and TMD and difficult airway management in obese patients, but there is no study examining the BRI-VIDIAC relationship.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

General anesthesia will be administered

Being classified as obese (BMI ≥30)

Patient giving informed consent

Disqualifiers

Pregnancy

Emergency surgery

Head and neck deformity

Inability to measure Mallampati level

Trial population

Participants aged 18-65 with a BMI ≥ 30 kg/m² who will undergo elective surgery.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • VIDEOLARYNGOSCOPE

    Device

    Videolaryngoscopy imaging in participants with a body mass index greater than 30 kg/m².

Treatment groups

90 Participants
are divided into 2 treatment groups
Group A: group 11 intervention
Group B: group 21 intervention

Trial outcomes

Primary outcomes

1

Examining the correlation between BRI and BMI values and the VIDIAC score.

To examine the correlation between BRI and BMI values and the VIDIAC score, and to determine whether BRI is a stronger predictor of difficult airway passage than BMI.

Time frame
3 minutes after anesthesia induction

Secondary outcomes

1

number of intubation attempts

To evaluate the relationship between BRI and BMI and the number of intubation attempts.

Time frame
3 minutes after anesthesia induction
2

Oropharyngeal visibility

To examine its relationship with oropharyngeal visibility (Cormack-Lehane, Mallampati).

Time frame
3 minutes after anesthesia induction

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.